PHG - Koninklijke Philips N.V.
NYSE
->
Healthcare
->
Medical Devices
Amsterdam,
Netherlands
Type: Equity
PHG price evolution
PHG
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3936 | $3953 | ||
| Inventory | $3612 | $3491 | ||
| Total current assets | $10138 | $9940 | ||
| Long term investments | ||||
| Property, plant & equipment | $2466 | $2483 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $29474 | $29406 | ||
| Current liabilities | ||||
| Accounts payable | $1850 | $1917 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8761 | $8287 | ||
| Long term debt | $7137 | $7035 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $17590 | $17378 | ||
| Shareholders' equity | ||||
| Retained earnings | $3732 | $6281 | ||
| Other shareholder equity | $1658 | $389 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 22 Feb 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2017.72 | $1227.6 | $2299.59 | $3226 |
| Short term investments | $591.6 | $653.6 | $555.18 | |
| Net receivables | $3953 | $4337 | $3961.12 | $4561 |
| Inventory | $3491 | $4049 | $3444.88 | $2993 |
| Total current assets | $9940 | $10259 | $10331.66 | $11227 |
| Long term investments | $21013.83 | $21398.2 | $20582.43 | $670 |
| Property, plant & equipment | $2483 | $2638 | $2695 | $2682 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $18830.82 | |||
| Total investments | ||||
| Total assets | $29406 | $30688 | $30914.09 | $27713 |
| Current liabilities | ||||
| Accounts payable | $1917 | $1968 | $1869.22 | $2119 |
| Deferred revenue | ||||
| Short long term debt | $706.04 | $975.17 | $505.25 | $886 |
| Total current liabilities | $8287 | $7934 | $7438.95 | $7735 |
| Long term debt | $7035 | $7270 | $6463.4 | $4757 |
| Total noncurrent liabilities | $9225.22 | |||
| Total debt | ||||
| Total liabilities | $17378 | $17439 | $16497.5 | $15812 |
| Shareholders' equity | ||||
| Retained earnings | $6281 | $8320 | $9344 | $7827 |
| Other shareholder equity | $389 | $377 | $1092 | -$340 |
| Total shareholder equity | $12985.07 | $13877.56 | $14417.59 | $11870 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $18169 | $17827 | $19535 | |
| Cost of revenue | $10754 | |||
| Gross Profit | $7448 | $7232 | $8781 | |
| Operating activities | ||||
| Research & development | $1783 | |||
| Selling, general & administrative | $5107 | |||
| Total operating expenses | $7555 | $7372 | $17653 | |
| Operating income | $1882 | |||
| Income from continuing operations | ||||
| EBIT | $1882 | |||
| Income tax expense | -$73 | -$113 | $284 | |
| Interest expense | -$411 | -$154 | -$160 | |
| Net income | ||||
| Net income | -$466 | -$1608 | $1187 | |
| Income (for common shares) | $1187 | |||
| (in millions $) | 30 Jul 2024 | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$338 | -$636 | -$359 | -$1487 |
| Financing activities | ||||
| Dividends paid | -$1 | -$2 | -$1 | -$412 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $350 | -$848 | -$168 | $500 |
| Effect of exchange rate | $24 | -$79 | -$47 | $41 |
| Change in cash and equivalents | -$63 | $696 | -$214 | -$1131 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 22 Feb 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $3313.08 | $1187 | ||
| Operating activities | ||||
| Depreciation | $1321.04 | $938 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $1625.59 | $2689 | ||
| Investing activities | ||||
| Capital expenditures | -$761.87 | -$513 | ||
| Investments | -$66 | |||
| Total cash flows from investing | -$636 | -$1487 | -$3667.55 | -$1316 |
| Financing activities | ||||
| Dividends paid | -$2 | -$412 | -$1 | |
| Sale and purchase of stock | ||||
| Net borrowings | $4113.89 | $783 | ||
| Total cash flows from financing | -$848 | $500 | -$2344.52 | $483 |
| Effect of exchange rate | -$79 | $41 | -$55 | |
| Change in cash and equivalents | $696 | -$1131 | -$1200.44 | $1801 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.34 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |